Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 22, 2026 (Updated: June 10, 2026)

The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains

Innovent advances a trispecific antibody into phase 3 multiple myeloma testing, Bionyra enters the crowded TL1A race in inflammatory bowel disease, and Insilico Medicine partners with SK Biopharmaceuticals to apply AI to neuroimmune and CNS drug discovery.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we're looking at three stories that highlight where innovation is heading across oncology, immunology, and artificial intelligence. From next-generation antibody engineering to the continued rush into inflammatory bowel disease and the growing role of AI in drug discovery, companies are pursuing new approaches to address difficult diseases and improve development efficiency.

First up, Innovent Biologics has advanced its trispecific antibody IBI3003 into a phase 3 clinical trial for relapsed or refractory multiple myeloma. The investigational therapy simultaneously targets BCMA and GPRC5D on myeloma cells while engaging CD3 on T cells. The design aims to improve tumor targeting while reducing the risk of antigen escape, a challenge that can limit the durability of some targeted therapies. The move into Phase 3 places IBI3003 among a growing group of next-generation immune therapies seeking to improve outcomes for patients whose disease has progressed after multiple prior treatments.

Next, a newly launched company is making a sizable bet on one of the most closely watched targets in immunology. Bionyra Pharma emerged with $165 million in financing and two TL1A-targeting biologics licensed from TrueLab. TL1A has attracted significant industry attention as companies pursue new treatments for inflammatory bowel disease. Several large pharmaceutical companies have already entered the space, creating a competitive race to determine whether targeting TL1A can offer meaningful benefits beyond current therapies. Bionyra's launch underscores the continued investor interest in inflammation and autoimmune disease programs despite increasing competition.

Finally, Insilico Medicine and SK Biopharmaceuticals have announced a collaboration focused on AI-powered drug discovery for neuroimmune and central nervous system disorders. The partnership will combine Insilico's artificial intelligence platforms with SK's neuroscience expertise to identify and develop new therapeutic candidates. Neuroimmune diseases remain among the most complex areas of drug development, and companies are increasingly turning to AI tools to help uncover novel targets and accelerate early-stage research.

From engineered antibodies to computational drug discovery, today's stories illustrate how biopharma companies are combining biology and technology to tackle some of medicine's most challenging diseases.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Innovent's Phase 3 advancement of IBI3003 highlights growing interest in trispecific antibodies as a potential next step in multiple myeloma treatment.
  • Bionyra's $165 million launch reflects continued enthusiasm for TL1A as a target in inflammatory bowel disease despite an increasingly crowded field.
  • AI-driven partnerships continue to expand beyond traditional drug discovery into complex neuroimmune and CNS disorders.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more